Dermata Therapeutics, Inc. (DRMA)
Data as of , from SEC Form 4 filings.
No open-market insider trades (90d)Watch DRMA
See up to 3 months of DRMA. The 7-day demo opens the 1M and 3M ranges and puts DRMA on your watchlist.
Start 7-day demoLatest DRMA insider trades
- Kathleen D. Scott - DirectorOpen-market sale$13
Munera Maria E. Bedoya-Toro - OfficerOpen-market purchase$1K- Gerald T. Proehl
About Dermata Therapeutics, Inc. (DRMA)
Dermata Therapeutics, Inc. files with the SEC under CIK 0001853816 and is classified as pharmaceutical preparations. We track it alongside the rest of the Health Care sector.
DRMA Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 9 | 4,897,956 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
DRMA insider transactions (Form 4)
3517 Form 4 filings on record, the earliest from Dec 30, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Gerald T. Proehl - Officer | Grant or award | Common Stock | 170,068 | - footnote F2 | - | |
| Gerald T. Proehl - Officer | Grant or award | Series E Warrant (Right to Buy) | 1,360,544 | - footnote F2 | - | |
| Gerald T. Proehl - Officer | Grant or award | Series F Warrant (Right to Buy) | 1,360,544 | - footnote F2 | - | |
| Gerald T. Proehl - Officer | Grant or award | Series E Warrant (Right to Buy) | 170,068 | - footnote F2 | - | |
| Gerald T. Proehl - Officer | Grant or award | Series F Warrant (Right to Buy) | 170,068 | - footnote F2 | - | |
| Gerald T. Proehl - Officer | Grant or award | Pre-Funded Warrant (Right to Buy) | 1,360,544 | - footnote F2 | - | |
| ||||||
 Hoose Kyri K. van - Officer | Grant or award | Common Stock | 102,040 | - footnote F2 | - | |
| Hoose Kyri K. van - Officer | Grant or award | Series E Warrant (Right to Buy) | 102,040 | - footnote F2 | - | |
| Hoose Kyri K. van - Officer | Grant or award | Series F Warrant (Right to Buy) | 102,040 | - footnote F2 | - | |
| ||||||
| Kathleen D. Scott - Director | Open-market sale | Common Stock | 11 | $1.19 | $13 | |
| Munera Maria E. Bedoya-Toro - Officer | Open-market purchase | Common Stock | 1,000 | $1.27 | $1K | |
| Gerald T. Proehl - Officer | Grant or award | Stock Option (right to buy) | 37,500 | $0.00 | - | |
| Wendell Wierenga - Director | Grant or award | Stock Option (Right to Buy) | 2,500 | $0.00 | - | |
 David F. Hale - Director | Grant or award | Stock Option (Right to Buy) | 2,500 | $0.00 | - | |
| Munera Maria E. Bedoya-Toro - Officer | Grant or award | Stock Option (right to buy) | 9,000 | $0.00 | - | |
| Kathleen D. Scott - Director | Grant or award | Stock Option (Right to Buy) | 2,500 | $0.00 | - | |
 Andrew Seth Sandler - Director | Grant or award | Stock Option (Right to Buy) | 2,500 | $0.00 | - | |
 Christopher J. Nardo - Officer | Grant or award | Stock Option (right to buy) | 18,000 | $0.00 | - | |
 Steven J. Mento - Director | Grant or award | Stock Option (Right to Buy) | 2,500 | $0.00 | - | |
| Hoose Kyri K. van - Officer | Grant or award | Stock Option (right to buy) | 18,000 | $0.00 | - | |
| Mary Fisher - Director | Grant or award | Stock Option (Right to Buy) | 2,500 | $0.00 | - | |
 Brittany Bradrick - Director | Grant or award | Stock Option (Right to Buy) | 2,500 | $0.00 | - | |
| Hoose Kyri K. van - Officer | Grant or award | Common Stock | 122,549 | - footnote F2 | - | |
| Hoose Kyri K. van - Officer | Grant or award | Series C Warrant (Right to Buy) | 122,549 | - footnote F2 | - | |
| Hoose Kyri K. van - Officer | Grant or award | Series D Warrant (Right to Buy) | 122,549 | - footnote F2 | - | |
| Hoose Kyri K. van - Officer | Derivative | Warrant (Right to Buy) | 7,874 footnote F3 | - footnote F6 | - | |
| Hoose Kyri K. van - Officer | Grant or award | Warrant (Right to Buy) | 7,874 footnote F3 | - footnote F6 | - | |
| ||||||
| Gerald T. Proehl - Officer | Grant or award | Common Stock | 490,196 | - footnote F2 | - | |
| Gerald T. Proehl - Officer | Grant or award | Common Stock | 122,549 | - footnote F2 | - | |
| Gerald T. Proehl - Officer | Grant or award | Series C Warrant (Right to Buy) | 490,196 | - footnote F2 | - | |
| Gerald T. Proehl - Officer | Grant or award | Series D Warrant (Right to Buy) | 490,196 | - footnote F2 | - | |
| Gerald T. Proehl - Officer | Grant or award | Series C Warrant (Right to Buy) | 122,549 | - footnote F2 | - | |
| Gerald T. Proehl - Officer | Grant or award | Series D Warrant (Right to Buy) | 122,549 | - footnote F2 | - | |
| Gerald T. Proehl - Officer | Derivative | Warrant (Right to Buy) | 78,740 footnote F3 | - footnote F7 | - | |
| Gerald T. Proehl - Officer | Grant or award | Warrant (Right to Buy) | 78,740 footnote F3 | - footnote F7 | - | |
| ||||||
Item 1.01, 3.02, 8.01, 9.01
Item 2.02, 9.01
Item 8.01
Item 5.02, 5.07, 9.01
DRMA insider trading FAQ
What is the latest insider trade for DRMA?
Dermata Therapeutics, Inc. (DRMA) had 2 insider filings in the last 90 days, with the most recent on 2026-08-18. The full record for DRMA runs to 17 Form 4 filings, the earliest from 2025-12-30. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying DRMA stock?
No insider purchases of DRMA were filed in the last 90 days. 1 purchase is on record for this company.
How many insiders are selling DRMA stock?
No insider sales of DRMA were filed in the last 90 days. 1 sale is on record for this company.
Where can I see DRMA SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects DRMA Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Gerald T. Proehl view on EDGAR
- - Hoose Kyri K. van view on EDGAR
- - Kathleen D. Scott view on EDGAR
- - Munera Maria E. Bedoya-Toro view on EDGAR
- - Gerald T. Proehl view on EDGAR
- - Wendell Wierenga view on EDGAR
- - David F. Hale view on EDGAR
- - Munera Maria E. Bedoya-Toro view on EDGAR
- - Kathleen D. Scott view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where DRMA's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow DRMA with a 7-day demo
- DRMA on your watchlist
- Every DRMA Form 4 filing on record
- Up to 3 months of DRMA price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
